A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2
about
Phage display--a powerful technique for immunotherapy: 2. Vaccine deliveryVLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusDurable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopesVLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation.Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizingReevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types.Development of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathway.A cholesterol-lowering VLP vaccine that targets PCSK9Optimization of multimeric human papillomavirus L2 vaccines.Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.Immunoprevention of human papillomavirus-associated malignanciesIdentification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine.Second-generation prophylactic HPV vaccines: successes and challenges.Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platformPreclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal AntibodiesHPV vaccination for prevention of skin cancer.Intracellular delivery of messenger RNA by recombinant PP7 virus-like particles carrying low molecular weight protamine.Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck.Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Evidence that viral RNAs have evolved for efficient, two-stage packaging.Laboratory and clinical aspects of human papillomavirus testingOptimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human PapillomavirusInfluence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccineProgress and prospects for L2-based human papillomavirus vaccinesBroad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants.Virus-like particles for the prevention of human papillomavirus-associated malignancies.Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope.Expanded strain coverage for a highly successful public health tool: prophylactic 9-valent human papillomavirus vaccine.Virus-based nanoparticles as platform technologies for modern vaccines.Developments in L2-based human papillomavirus (HPV) vaccines.Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature.HPV vaccines: Global perspectives.PhiXing-it, displaying foreign peptides on bacteriophage ΦX174.
P2860
Q26865013-C9AD134B-2332-4D69-8CB1-70EDCE754BD8Q28280059-1EED88D3-E057-4C9B-BDAE-5CAE138FFD2BQ28603888-8035A86B-A047-49A7-BDBA-E2FACD8E42A3Q33677615-7C3B6F9D-6AD4-4DAB-A332-2AA41B9AA8E9Q33856453-F5D8F2EA-6D4D-417C-8572-45397EC2116EQ33967341-0B4D2A54-B378-44D2-B142-12891B5A254EQ34370578-BC3D8D29-1D7E-4814-A86D-391883692D00Q34472793-2ACBF0D7-989A-4988-A810-052EB1C86020Q34496015-935D2B6A-F4EF-4D9A-8C7A-476D621833CBQ34576677-5712AF55-49B2-4C58-8D8F-BF354BBE7533Q34639978-28EF507A-F60D-4848-A0AE-70BA32CA69C9Q35044376-A59FB8E2-350C-44FB-9046-822296289143Q35532771-776C362E-1A49-4E42-916E-A11BEEFED123Q35541210-AF80CE11-0974-4312-87AC-7E2577012930Q35541886-32B0F17F-9B0F-40D2-9993-6474DF1D6261Q35591551-135B917C-71B4-4BC9-A75E-C86D7259145CQ35744303-5EB59A40-47CB-4AE2-80AD-8500817DB5FDQ35773930-DE8828D9-33A8-4872-8719-18A74DC3E9DDQ35887782-DB0998BE-9DBD-4E5B-836F-EC3001434242Q36032757-B54652C9-52DC-44E1-9E56-6ADC4501C2CFQ36088069-4E344212-7A27-4A76-A9AA-8759E6D6E4E5Q36240497-78BED9D3-9E01-4136-A8F5-C602683EE989Q36300706-CD2F258E-A5F2-42EA-8E84-5CB6F8D51D3CQ36311573-999680EC-ECBF-417B-8956-987E96FA1824Q36858686-C6AF9C94-8F03-4154-9702-C78FF70CCB6BQ36970255-D3FB484C-23D3-4D4C-B5FD-9E3E0D4C6A90Q37014047-5AF3402B-3584-489D-B6D1-7708B869344FQ37073299-D440C6D5-82A9-44DC-8396-3918360AA5B4Q37202927-EC2C103D-03E6-45ED-81A3-9382A7D1EF3DQ37328475-3E404DA8-F7AB-4361-8C83-D9DDEAC200E6Q37599123-84CBF71A-983D-45C3-9D74-DC0BF4799A13Q37714750-9674A90D-2B4E-4D1E-9FE1-18A589B89929Q38682763-2FEA208F-C5CD-40D8-8283-83F92AD25659Q38702017-91B57F97-D765-4A8B-8C33-023B72E43E64Q39021001-E31B5C33-5AFC-41E0-A4F3-26FC7DA9E57CQ39084400-CBCA08C3-4529-4F65-BA73-FEBB7149DA38Q39229099-B67BC9E9-9DA0-46AE-B382-DB16C60BCC2EQ40117882-0E5CA24C-3C51-417B-B32F-A324F8CC6EBBQ40265515-72345469-2615-41E9-94A0-C9FD6B2B59FEQ40876140-1868BBE1-CF4D-414F-82E4-BEBCC4DD4ADB
P2860
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@ast
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@en
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@nl
type
label
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@ast
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@en
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@nl
prefLabel
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@ast
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@en
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@nl
P2093
P2860
P3181
P1433
P1476
A pan-HPV vaccine based on bac ...... e HPV minor capsid protein, L2
@en
P2093
Bryce Chackerian
David S Peabody
Ebenezer Tumban
Julianne Peabody
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0023310
P407
P577
2011-01-01T00:00:00Z